Goldman Sachs Group Inc Uro Gen Pharma Ltd. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 424,916 shares of URGN stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

424,916

Previous 290,577 46.23%

Holding current value

$10.3 Million

Previous $3.98 Million 108.39%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$12.96 - $21.42 $1.74 Million - $2.88 Million	134,339 Added 46.23%	424,916 $8.29 Million
Q2 2025 Aug 14, 2025	BUY	$3.9 - $15.46 $24,347 - $96,516	6,243 Added 2.2%	290,577 $3.98 Million
Q1 2025 May 09, 2025	SELL	$9.27 - $12.13 $307,652 - $402,570	-33,188 Reduced 10.45%	284,334 $3.14 Million
Q4 2024 Feb 11, 2025	BUY	$10.52 - $13.11 $16,463 - $20,517	1,565 Added 0.5%	317,522 $3.38 Million
Q3 2024 Nov 14, 2024	BUY	$12.7 - $17.92 $664,857 - $938,129	52,351 Added 19.86%	315,957 $4.01 Million

Q2 2024 Aug 13, 2024	BUY	$12.72 - $19.2 $1.9 Million - $2.88 Million	149,744 Added 131.51%	263,606 $4.42 Million
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $4,957 - $6,939	-359 Reduced 0.31%	113,862 $1.71 Million
Q4 2023 Feb 13, 2024	BUY	$10.87 - $15.93 $658,439 - $964,943	60,574 Added 112.91%	114,221 $1.71 Million
Q3 2023 May 14, 2024	SELL	$8.84 - $22.64 $535,474 - $1.37 Million	-60,574 Reduced 53.03%	53,647 $751,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $196,813 - $504,056	22,264 Added 70.94%	53,647 $751,000
Q2 2023 May 14, 2024	SELL	$8.75 - $14.29 $342,755 - $559,767	-39,172 Reduced 55.52%	31,383 $324,000
Q2 2023 Aug 14, 2023	SELL	$8.75 - $14.29 $342,755 - $559,767	-39,172 Reduced 55.52%	31,383 $324,000
Q1 2023 May 14, 2024	BUY	$7.99 - $11.02 $376,169 - $518,821	47,080 Added 200.55%	70,555 $651,000
Q1 2023 May 11, 2023	BUY	$7.99 - $11.02 $376,169 - $518,821	47,080 Added 200.55%	70,555 $651,000
Q4 2022 May 14, 2024	SELL	$7.55 - $11.96 $883 - $1,399	-117 Reduced 0.5%	23,475 $208,000
Q4 2022 Feb 13, 2023	SELL	$7.55 - $11.96 $883 - $1,399	-117 Reduced 0.5%	23,475 $208,000
Q3 2022 May 14, 2024	SELL	$7.21 - $9.41 $105,576 - $137,790	-14,643 Reduced 38.3%	23,592 $196,000
Q3 2022 Nov 10, 2022	SELL	$7.21 - $9.41 $105,576 - $137,790	-14,643 Reduced 38.3%	23,592 $0
Q2 2022 May 14, 2024	SELL	$5.12 - $8.74 $389,048 - $664,117	-75,986 Reduced 66.53%	38,235 $313,000
Q2 2022 Aug 15, 2022	SELL	$5.12 - $8.74 $58,854 - $100,466	-11,495 Reduced 23.11%	38,235 $313,000
Q1 2022 May 16, 2022	SELL	$5.92 - $9.73 $25,118 - $41,284	-4,243 Reduced 7.86%	49,730 $434,000
Q4 2021 Feb 14, 2022	SELL	$9.03 - $19.13 $28,959 - $61,349	-3,207 Reduced 5.61%	53,973 $513,000
Q3 2021 Nov 10, 2021	BUY	$14.31 - $18.39 $818,245 - $1.05 Million	57,180 New	57,180 $962,000

Others Institutions Holding URGN

# of Institutions

171

Shares Held

43.8M

Call Options Held

1.61M

Put Options Held

433K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $553M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Uro Gen Pharma Ltd. Transaction History